Evidence map›Paper›PMID 41326940›Full record

ReviewHepatology international2026

Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.

Atsushi Tanaka, Sombat Treeprasertsuk, Ming-Ling Chang, Soek-Siam Tan, Cumali Efe, Sook-Hyang Jeong, Xiong Ma, Martin Weltman, Hiroyuki Isayama, Jidong Jia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Atsushi TanakaDepartment of Medicine, School of Medicine, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. a-tanaka@med.teikyo-u.ac.jp.ORCID http://orcid.org/0000-0002-6358-5283
Sombat TreeprasertsukDivision of Gastroenterology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Ming-Ling ChangDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taiwan.
Soek-Siam TanDepartment of Hepatology, Selayang Hospital, Batu Caves, Malaysia.
Cumali EfeDepartment of Gastroenterology, Faculty of Medicine, Harran University, Sanlıurfa, Turkey.
Sook-Hyang JeongDepartment of Internal Medicine, College of Medicine, Seoul National University, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea.
Xiong MaDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Mainland, China.
Martin WeltmanDepartment of Gastroenterology and Hepatology, Faculty of Medicine and Health, Nepean Hospital, and University of Sydney, Sydney, Australia.
Hiroyuki IsayamaDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Jidong JiaLiver Research Center, National Clinical Research Center of Digestive Diseases, State Key Laboratory of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, Mainland, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsAutoimmune liver diseases (AILD) have historically been considered uncommon in the Asia-Pacific region, where viral hepatitis has predominated as the leading cause of chronic liver disease. However, their recognition and clinical relevance have increased substantially in recent years, mirroring global epidemiologic trends. This proceedings report summarizes the educational course on AILD held during the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) in 2025, highlighting contemporary insights into disease burden, diagnosis, and management across diverse populations.

methodsInternational experts presented updated evidence and region-specific considerations concerning autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and IgG4-related sclerosing cholangitis. Key advances in risk stratification, imaging, serology, patient-reported outcome measures (PROMs), and emerging therapeutics were synthesized.

resultsImportant updates included improved understanding of acute presentations of AIH, evolving risk stratification and second-line pharmacologic approaches in PBC, and advances in PSC diagnostics incorporating novel imaging modalities and emerging autoantibodies. The unique clinical phenotype and steroid responsiveness of IgG4-related sclerosing cholangitis were also emphasized. Increasing incorporation of PROMs into clinical practice and trials, as well as progress in targeted therapies-such as peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists, and ileal bile acid transporter inhibitors-reflects a shift toward precision medicine and improved quality of life.

conclusionsAILD represents a growing clinical challenge in the Asia-Pacific region. Earlier recognition, individualized treatment strategies, and strengthened multinational collaboration are essential to address unmet diagnostic and therapeutic needs and to improve long-term outcomes.

Indexed as

Cholangitis, SclerosingHepatitis, AutoimmuneLiver Cirrhosis, BiliaryAsiaHumansAutoimmune hepatitisDiagnosisEpidemiologyIgG4-related sclerosing cholangitisManagementPatient-reported outcomesPrimary biliary cholangitisPrimary sclerosing cholangitis

Identifiers

PMID41326940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.